Holen Sie sich die Stockscreener-App
1.96
2.00%
-0.04
Handel nachbörslich:
1.99
0.03
+1.53%
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Average Price Target from Brokerages - MarketBeat
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO's Next Big Move: CEO Reveals Future of DNA Medicine at Major Healthcare Conference - StockTitan
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Head to Head Review: Inovio Pharmaceuticals (NASDAQ:INO) and Hypertension Diagnostics (OTCMKTS:HDII) - Defense World
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP - MSN
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
Barclays PLC Buys 25,116 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 - MSN
What is HC Wainwright’s Estimate for INO FY2024 Earnings? - Defense World
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given New $3.00 Price Target at HC Wainwright - Defense World
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright - MarketBeat
JMP Securities Reaffirms “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles - Investing.com Australia
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles By Investing.com - Investing.com South Africa
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $11.50 - MarketBeat
Inovio Pharmaceuticals' (INO) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accom - GuruFocus.com
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments - Longview News-Journal
What's Going On With Inovio Pharmaceuticals (INO) Stock? - Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing - Benzinga
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by State Street Corp - Defense World
Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment - MSN
Inovio Completes Enrollment In The Phase 1 U.S. Trial Of Ino-4800 For Covid-19 Dna Vaccine Interim Results Expected In June - Reuters
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):